Compare TG Therapeutics Inc (TGTX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Under Armour Inc Class A — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Under Armour Inc Class A trades at $5.33 (market cap $2.26B). The key difference: TG Therapeutics Inc is far larger — about 3.4× Under Armour Inc Class A's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| TGTX | UAA | |
|---|---|---|
Market Cap | $7.64B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $8.14 |
52-Week Low | $26.94 | $4.17 |
Enterprise Value | $7.84B | $3.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Under Armour (UAA) is trading at $5.245, down 10.49% today, reflecting ongoing challenges with revenue declines and negative profitability. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal a net loss of -$201.27M in 2025 and negative cash flow trends. Recent Q1 2027 earnings beat expectations but revealed weaker revenue and cautious guidance, with management maintaining profitability outlook despite sales headwinds.
The outlook remains challenging with declining revenues and negative margins, though current valuation metrics appear reasonable. Key risks include weak North American demand and competitive pressures, while potential catalysts include new product collaborations and cost management. Analyst consensus is mixed with 27% buy ratings but a $6.67 price target suggesting 27% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
